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Commentary: 
 
Before the advent of tyrosine kinase inhibitor (TKI) therapy, BCR-ABL1/Philadelphia 
chromosome positive ALL (Ph+ALL) carried an exceptionally poor prognosis and was a definite 
indication for allogeneic hematopoietic stem cell transplantation (HSCT). Adding TKI to 
frontline therapy improved survival and transplantation was increasingly reserved for poor 
responders in paediatric patients. The study by Biondi et al. in this issue of Lancet 
Haematology(1) confirms previous findings that earlier initiation and prolonged, continuous 
TKI administration together with intensive chemotherapy increase morphologic and 
molecular response rates in Ph+ ALL.(2, 3) Notably, response in the EsPHALL2010 trial 
compared favorably with the preceding study particularly in poor risk patients, with similar 
overall and disease-free survival.(4) This supports the tenet that reliance on HSCT can be 
reduced without compromising outcome but relapse, treatment-associated mortality and 
morbidity remain serious limitations in transplanted and in chemotherapy-only cohorts.  
Which patients actually benefit from HSCT? Best outcomes in terms of DFS occurred in the 
good risk (GR) group achieving early minimal residual disease (MRD) negativity, whereas MRD 
poor risk (PR) patients and those with higher WBC count who underwent HSCT in first CR had 
inferior (albeit not statistically significant) DFS. This challenges the widely accepted transplant 
strategy for children with Ph+ALL, with implications for designing future treatment of poor 
risk patients. GR patients fared significantly better with HSCT in terms of relapse incidence and 
event-free survival (EFS) but not overall survival, an observation that differs substantially from 
adult Ph+ALL, where avoidance of relapse is critical. Although deferring HSCT to more 
advanced disease is accepted practice in children owing to the efficacy of salvage therapy, the 
outcome of these patients reported by Biondi et al. remains unsatisfactory. 
Given its non-randomized study design and the changing indications for HSCT during protocol 
accrual, the EsPhALL2010 study does not conclusively resolve the controversy surrounding 
eligibility for HSCT. Post amendment, poor risk pts were not transplanted in case of a good 
MRD response, but MRD data were available for only about half of patients enrolled, and pre-
transplant MRD values were often lacking. Thus, it is unclear how the indications for HSCT 
(poor MRD response) would have been determined in patients without having at least one 
MRD analysis performed during therapy. Moreover, the potential of post-transplant 
intervention with TKI has most likely not been fully exploited in this trial. 
MRD measurements were based on quantitation of immunoglobulin(Ig)/T-cell receptor (TCR) 
gene rearrangements rather than on quantitation of BCR-ABL1 transcripts. Recent studies 
have demonstrated that results generated by these methods may be discordant, particularly 
in cases with p210BCR-ABL1.(5, 6) As the underlying biological differences are likely to be clinically 
relevant and have implications for treatment, future MRD testing should employ both 
methods in parallel.  
The relevance of biologic and genetic factors in pediatric and adult Ph+ALL has become 
increasingly appreciated but is hardly addressed by this EsPhALL trial. A negative impact of 
high WBC (>1x105/µl) was noted but the molecular mechanisms underlying the inferior 
outcome of these patients, or those in the GR group who nevertheless experience late 
relapses remain elusive. Similarly, the study did not evaluate the role of recurrent genomic 
alterations such deletions in IKZF1 which have been linked to inferior outcome in several 
studies, including a COG trial of dasatinib plus chemotherapy,(7) or applicability of the recently 
described inverse correlation between number of genetic lesions and outcome to this 
population.(8) It therefore remains unclear whether presence of these genetic lesions 
correlates with MRD response, WBC at diagnosis or outcome in relation to HSCT or non-
transplant therapy. Such integrated analysis of MRD, genomic and clinical data will be needed 
to identify novel, independent biomarkers for outcome in future trials. 
Improving outcomes requires increasing treatment efficacy while reducing the toxic death 
rate associated with current intensive regimens. Published data in adult Ph+ALL demonstrate 
lower early morbidity and mortality without compromising long-term outcome when imatinib 
is combined with minimal chemotherapy during induction.(9) More potent TKI may further 
augment rates and depth of molecular response.(10) Conversely, post-remission treatment 
intensity remains important for treatment with curative intent. Addition of novel treatment 
elements able to induce MRD negativity while adding only moderate toxicity, e.g. 
immunotherapy, has the potential to improve post-transplant outcome particularly of PR 
patients who did not benefit from HSCT, or even obviate the need for HSCT. It is plausible that 
such novel regimens will also benefit the group of GR patients when incorporated into 
frontline therapy. Evaluation of novel therapeutic interventions and algorithms for clinical 
decisions in this rare subgroup of childhood ALL will require ambitious, multinational trials 
exemplified by this study of the EsPhALL consortium.   
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